Bio-Bridge Science Inc (OTC:BGES)

Bio-Bridge Science, Inc. is a development stage company whose subsidiaries are focused on the commercial development of HIV-PV Vaccine I, HPV vaccine, colon cancer vaccine, mucosal adjuvant. The pre-clinical testing of HIV-PV Vaccine I on laboratory animals in Beijing, China was completed in June 2006. After the lab equipment is installed and we are able to produce vaccine candidate samples, we will apply to China's State Food and Drug Administration for approval to conduct clinical trials of HIV-PV Vaccine I. As of December 31, 2005, we had completed the construction of the outside body of our laboratory and bio-manufacturing facility in Beijing, China. The internal clean room installation project has been substantially completed as of end of 2006.

The GeoTeam is coding this company as china because of a recently announced relationship with a Chinese firm. This relationship will result in BGES having a 50% ownership stake in the Chinese firm. :

Bio-Bridge Science Signs an Equity Sale and Purchase Agreement with Xinheng Baide Biotechnology Co. Ltd.

BGES shall control 51% of the outstanding capital stock of Xinheng Baide Biotechnology Co. Ltd.

Source: Business Wire (May 1, 2008)

Reverse Merger Filings